March 4th 2024
Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine.
November 30th 2023
November 20th 2023
Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.
Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.
Results of the FRAIL-AF trial at ESC Congress 2023 provide clinicians with further clarity into the effects of switching from vitamin K antagonists to NOACs in older patients with frailty and atrial fibrillation.
This cardiology case report from Brady Pregerson, MD, features man in his late-60s presenting to urgent care with 3 days of upper respiratory infection symptoms and one episode of near syncope. Check out the ECG and see if you can determine the correct diagnosis!
Presented at the European Stroke Conference, results of the ELAN trial offer evidence in support of early initiation, as opposed to later initiation, strategies for anticoagulation following acute ischemic stroke in patients with atrial fibrillation.
An analysis of more than 1 million AFib hospitalizations suggests those with large vessel vasculitis had a nearly 2-fold increase in risk of acute myocardial infarction and a more than 9-fold increase in risk of acute kidney injury.
An analysis of data from 3 European countries provides insight into the apparent increase in risk of atrial fibrillation associated with preterm births as well as LGA or SGA births.
Using data from more than 800 older patients, new research is shining a light on the potential reduction in cognitive decline seen with the use of catheter ablation among patients with atrial fibrillation relative to medical management.
A retrospective analysis of more than 60 patients 21 years or younger who received a transcatheter leadless pacemaker provides an overview of the safety of such an approach in younger patient populations.
The randomized AWARE trial indicates patients with paroxysmal AF did not have improved freedom from recurrent atrial arrhythmia with a double ablation lesion set compared with a single procedure.
New data from a predefined secondary analysis of the STROKE-AF trial provides insight into the 3-year incidence of atrial fibrillation among patients with a history of ischemic stroke caused by atherosclerosis.
On February 2, Abbott announced their FlexAbility™ Ablation Catheter, Sensor Enabled had received an expanded approval from the US Food and Drug Administration and their TactiFlex™ Ablation Catheter, Sensor Enabled received a CE Mark.